BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

Core Insights - BioXcel Therapeutics, Inc. is participating in the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, where CEO Vimal Mehta will discuss the company's initiatives [1] - The company utilizes artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology [3] Company Overview - BioXcel Therapeutics, Inc. (NASDAQ:BTAI) focuses on drug re-innovation by leveraging existing approved drugs and big data to identify new therapeutic indications [3] - The company's subsidiary, OnkosXcel Therapeutics, is dedicated to developing medicines in immuno-oncology [3] Event Details - The fireside chat will be accessible via a live webcast on the company's website, with a replay available for 90 days [2]